Integrated DNA Technologies Acquires 1st BASE Oligonucleotide Business in Singapore
News Feb 09, 2012
Dr. Joseph Walder, IDT’s founder and Chief Executive Officer, stressed the commonalities that brought 1st BASE and IDT together. “We found natural partners in the people at 1st BASE, with whom we’ve been working for many years,” he noted. “Above all, IDT and 1st BASE shared a commitment both to consistently high-quality oligos and to personal service for customers, who we consider collaborators.” “As we thought about how to deliver the IDT advantage to scientists in Asia,” he added, “working with the 1st BASE team became the obvious choice.”
In recognition of 1st BASE’s leadership among the region’s oligo providers, IDT has named its new company in Singapore 1st BASE Custom Oligos Pte. Ltd. (FBCO), and IDT will retain the “1st BASE” brand for the small scale DNA oligos that it synthesizes in Singapore.
Mr. Kok Choy “KC” Lee, 1st BASE’s Chief Executive Officer, has become the General Manager of FBCO and a member of IDT’s leadership in Asia. “I and all of my team are honored to become part of the IDT family,” he said, “because we know that research scientists in Singapore and throughout our region will soon have direct access to what makes IDT unique.” “Our job now is to couple IDT’s unequaled synthesis capabilities and design expertise with the fast turnaround times and personal customer service that operating locally makes possible,” he added.
“We’re just getting started in Asia, and we have a lot to learn about the needs of researchers working here,” Dr. Walder noted. “There’s certainly more to come,” he predicted. “But with FBCO up and running, and with the support of our new colleagues from 1st BASE, we aim to build on IDT’s success in North America and in Europe by bringing to Asia the very best in custom biology products.”
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE
Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden. According to a new study, pollen allergen immunotherapy has favorable effects on the molecular events and microbiome profile in the nasal membrane.READ MORE
In a study of mice and human brain tumors researchers searched for new treatments by exploring the reasons why some patients with gliomas live remarkably longer than others. The results suggested that certain patients’ tumor cells are less aggressive and much better at repairing DNA than others but are difficult to kill with radiation.READ MORE